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One third of all breast cancers occur in women over the age of 70.  Breast cancer specific outcomes in this age group 
are inferior to those of younger women due to a combination of later stage at diagnosis and reduced treatment 
schedules.  The latter are selected to minimise morbidity in a population with higher rates of comorbidity and frailty.  
One such treatment strategy is primary endocrine therapy (PET), where for women with potentially operable, 
oestrogen receptor positive (ER+) cancers surgery may be omitted in favour of anti-oestrogens alone.  Twenty years 
ago, several randomised trials demonstrated that PET, whilst associated with lower rates of local disease control 
compared to surgery, offered equivalent overall survival rates.  These trials were all flawed in not testing the ER 
receptor status of the cancer and not selecting a cohort of frailer women as would happen in current clinical 
practice.  The data from these trials may therefore not be valid in modern practice. 
In the UK up to 40% of women over 70 are treated with PET although there is a high rate of variability of practice 
between centres reflecting a lack of guidance about case selection.   It is likely that in frailer women with confirmed 
ER positive cancers, PET may be an effective alternative to surgery This systematic review of the literature relating to 
PET has included not only the RCT data but also cohort study data of actual clinical practice to try to establish if this 
form of treatment is still valid in modern breast practice 





Breast cancer incidence increases with age, with over 30% of breast carcinomas occurring in women aged 70 and 
older [1-3]. This incidence is set to rise even further as the UK population ages [4].  
Elderly women are more likely to be diagnosed with oestrogen receptor (ER) positive breast cancers [5] and 
therefore be responsive to anti-oestrogen therapy, hence the use of primary endocrine therapy (PET) in this age 
group. Tamoxifen as PET was introduced and proved effective for the treatment of breast cancer in the 1980s [6], 
after which it rapidly gained popularity in the UK as a management strategy for older women. This lead to a number 
of randomised controlled trials (RCTs) aimed at comparing the efficacy of PET against surgery in older patients. In 
total 7 RCTs were performed internationally, all assessing Tamoxifen, although a variety of designs and comparisons 
were used. A Cochrane meta-analysis demonstrated superior local control with surgery but no increased survival 
benefit. As a result of this, more recent studies have advocated the use of PET only for the very frail or very old [7,8]. 
This has a huge impact of the applicability of the RCT data to modern day clinical practice as all the included patients, 
by their very nature, were deemed fit enough for surgical treatment. In addition, since this data was published, 
Tamoxifen has largely been replaced by the third generation aromatase inhibitors as first line treatment for both PET 
and adjuvant therapy, again limiting the applicability of these earlier RCT results. Additionally, since the first studies 
on PET were published, other significant advances have been made in terms of the widespread availability of ER 
testing and improvements in anaesthetic techniques meaning that breast surgery today, even in the older patient, 
has a very low morbidity and mortality. This can be seen in the recent UK wide National Mastectomy and 
Reconstruction Audit, where the overall mortality rate was 0.26% [9].  However this may reflect the fact that the less 
fit, frailer patients were managed with PET as this remains a widespread option for those considered at higher risk of 
surgery with 93% of UK surgeons using this option for some patients [10]. Several recent studies have found that up 
to 40% of patients over 70 years old are treated with PET in the UK [11,12]. Additionally, there have been several 
new studies published within the last two years looking at cohorts of women treated using PET [13-22]. The 
methodology of these cohort studies vary greatly, particularly in terms of the treatment used, the fitness of included 
patients and whether ER testing was performed, again limiting the overall applicability to modern clinical practice.  
With such changes occurring in this field and with new data being published so recently, we undertook an analysis of 
the data pertaining to PET that has been published in the literature since it was introduced as a treatment for 




A comprehensive search of the published literature was performed to identify studies that assess primary endocrine 
therapy in a clinical setting, by searching MEDLINE, EMBASE, CINHAL and PsychINFO databases. Searches were 
4 
 
limited to those published after 1980 and published in the English language. References of all retrieved and relevant 
publications identified by the search strategies were searched for further studies. 
A total of 6,629 results were generated by these initial searches. Abstracts and titles were reviewed for relevance 
and compared to the inclusion criteria and full text articles were obtained. Where it was unclear from the 
title/abstract whether the studies met the inclusion criteria, full text articles were also obtained and a decision made 
based on the entire paper. See Figure 1 for the review process.  
Exclusion criteria included studies where patients with stage IIIb or IV disease made up more than 30% of the 
population and those who were treated with neo-adjuvant endocrine therapy prior to surgery for a period of less 
than 6 months. 
Data was extracted pertaining to number of patients, type of anti-oestrogen  used, ER status, complete response 
rate (CR), partial response rate (PR), static disease (SD), progressive disease (PD), clinical benefit rate (CR + PR + SD), 
disease progression, breast cancer-specific survival (BCSS) and overall survival (OS). Data analysis was performed 






Results of the search:  
Six randomised controlled trials (see table 1) and 31 non-randomised studies (see tables 2a and 2b) were deemed 
eligible for inclusion in the final review. In addition, two large population-based studies which analysed registry data 
for older patients with breast cancer were also identified. The randomised controlled trials identified were the same 
as those published in a Cochrane review [23-25] and so these studies were not re-analysed but a brief overview will 
be presented here. 
Efficacy of PET. 
A total of 31 cohort studies assessed a total of 2874 patients who were treated with PET. Of these, only 12 studies 
included solely patients who had ER positive tumours, 12 studies included patients with ER positive and ER negative 
tumours and 7 studies didn’t assess ER status. Therefore the total number of patients in the studies including only ER 
positive tumours was 1417 and the number of patients in the studies including both ER positive and ER negative 
patients was 1348.  In general, the studies where ER was not known were less recent than those where ER status 
was known reflecting the increased availability of routine testing. 
Nineteen studies including 1256 patients used TAM only;  five studies including 325 patients used AIs only (Letrozole 
in three, Anastrazole in one and one did not specify); six studies including 1134 patients used both TAM and AIs; and 
one study that included 50 patients didn’t specify the type of PET used. 
Most studies included only elderly patients, with the average patient age being over 70 years. Follow-up length 
varied greatly, with the largest study having a follow-up range of between 1-202 months. 
Not all studies reported on all outcomes, however there were enough studies to meta-analyse data on clinical 
benefit and progression rate according to PET type¥ and ER status. Clinical benefit (CR+PR+SD) was higher in patients 
treated with an AI compared to patients treated with TAM (88% v 77%; p<0.01) and the rate of disease progression 
was lower in patients treated with AIs compared to TAM (31% vs. 46%; p<0.01).  
We also analysed studies according to whether they included only ER positive patients or not. Studies who only 
included ER positive patients has a higher clinical benefit rate (86% v 75% p<0.01), although the rate of disease 
progression was the same between groups (41% v 41%).  
Due to the large variation in follow-up length, it was not possible to analyse data on Breast Cancer Specific Survival 
or Overall Survival according to type of PET used or ER status.   
Surgery vs. PET. 
Six of the non-randomised studies, including 3559 patients, compared PET with surgery* – see tables 2a and 2b. 
Combining the results of the five studies that reported on OS revealed that there was a significantly higher overall 
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survival rate in patients treated with surgery when compared to those treated with PET (67% v 49% p<0.01). This is 
to be expected because of the likely difference in comorbidity, frailty and age between the PET and the surgery 
groups in a cohort study.   Looking at BCSS, five studies reported on this outcome and meta-analysis demonstrated 
that surgery was associated with a small but significantly higher BCSS rate when compared to PET (90% v 85% 
p<0.01).   The difference in effect size of the 2 treatments between surgery and PET arms comparing OS and BCSS is 
to be expected, again due to differing levels of comorbidity between the 2 groups.  To date, there have also been 
seven Randomised Controlled Trials (RCTs) that have compared survival outcomes of primary Tamoxifen with 
surgery (with or without Tamoxifen) for the treatment of operable breast cancer in older women. Based on 869 
deaths in 1671 women, meta- analysis was unable to demonstrate any significant difference between the two 
treatments in terms of overall survival when baseline patient characteristics are matched as in a RCT. However, PET 
was associated with a lower disease-free survival when compared to surgery due to a significantly increased rate of 
local disease progression in the breast in the PET arm of these trials.  
In addition, two large population-based cohort studies also compared outcomes in patients according to the type of 
treatment they received. These studies were not included in the above meta-analysis as they did not specifically 
assess the use of PET as a treatment for older women, instead they looked at differences in outcomes for patients 
treated with surgery vs. non-surgical treatment. Additionally, both studies obtained their results from cancer 
registries which leads to concerns regarding data quality; as such they were considered methodologically too 
different to include in the meta-analysis. Bouchardy et al [56] reviewed the outcomes of 407 breast cancer patients 
aged 80 years or over, treated between 1989 and 1999. They found that 5-year specific survival was low among 
women who were treated with Tamoxifen only (51%) when compared to those women treated with breast-
conserving surgery and adjuvant treatment (90%) [56]. More recently, Ali et al [57] reviewed the outcomes of 14 048 
women with breast cancer, who were aged 50 years or older and treated in the East of England between 1999 and 
2007. They also found that surgery was associated with superior overall survival relative to non-surgically treated 
women but selection bias for older, frailer women may have accounted for much of this difference and could not be 
corrected for due to innate limitations in registry data [57].  
 
Discussion 
When looking at the efficacy of PET, clinical benefit rates in elderly women with ER positive breast cancers are 
generally high and overall the cancer reduces in size or fails to progress in 75% of cases [23,24]. However, most of 
the original published RCTs recruited patients regardless of their ER status. Patients with moderate to strongly ER 
positive breast cancer can expect a good response in around 79-90%, this is in comparison to up to a 100% 
progression rate in patients with ER negative tumours [32,47,52,58-59]. This can be seen from the non-randomised 
data where there is a significantly higher response rate for those trials that included only ER positive patients.  
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Efficacy of PET also appears higher for patients treated with aromatase inhibitors rather that Tamoxifen, which is 
consistent with the findings from studies in other settings for this population, including the adjuvant, neo-adjuvant 
and metastatic settings, where aromatase inhibitors are well-established as the superior option [60-64].  
In terms of survival benefit, there is no clear advantage to either treatment shown by the meta-analysis of the RCTs 
published to date. However, many of these trials were flawed by modern standards, particularly with regards the 
treatment given; three out of the seven trials used a comparison of surgery only – when nowadays, all patients 
undergoing operative intervention would be treated with adjuvant endocrine therapy where appropriate. This is 
without taking into account modern surgical techniques, with adequate margins and the routine addition of 
radiotherapy to patients who undergo wide-local excision. 
Looking at the non-randomised studies, the combined data showed an advantage in terms of both overall and 
breast-cancer specific survival in favour of surgery. However, it must be noted that due to the selection criteria for 
these two groups of patients, particularly in terms of fitness for surgery and co-morbidities, the overall health status 
of the two populations are likely to be inherently different which will result in confounding when looking at OS as it 
includes all-cause mortality, something that would be expected to be higher in a less fit cohort. Breast cancer specific 
survival should be less subject to bias associated with baseline fitness levels between groups than overall survival 
and as this also favours surgery, this is of potential clinical significance. It suggests that in studies of what may be 
regarded as ‘normal clinical practice’ (as opposed to the artificial conditions imposed by RCTs) there is still some 
advantage to surgery except in women with a very high burden of comorbidity or frailty who die of non-breast 
cancer related diseases within a few years of diagnosis.  However there is another potential source of bias to 
consider: that of death certification. If a woman has had surgery and has no evidence of local recurrence and dies of 
unrelated illness, breast cancer may not be mentioned on the death certificate. If she is on PET and still has a 
palpable or visible breast cancer, she may be more likely to have the breast cancer listed as a contributing cause, 
even when this was not the case. This phenomenon is increasingly recognised as a potential bias in observational 
studies using death certification to assess cause of death [65]. 
The co-morbid status and ages of the patients varied greatly between randomised and non-randomised studies. Co-
morbidities have been demonstrated to have a significant impact on survival, and even those elderly women who 
are fit for surgery die of co-morbid diseases, thereby potentially reducing the survival advantage of any breast cancer 
therapies [66]. Mansi and colleagues [39] included a 29 year old patient in their study which, in terms of modern day 
practice, would be considered a wholly inappropriate indication for PET. The majority of studies took 70 years as a 
cut off for “elderly” and most did not comment on the level or type of co-morbidities, instead just quoting that 
included patients were “unfit” for surgery. Interestingly, one study that reported that 32% of included patients were 
unfit for surgery yet had a 93% 5-year survival rate which highlights how difficult predicting probable life expectancy 
can be [19]. Osborn and colleagues [15] in their study were the only authors to use a formal assessment of co-
morbidity. They used the Charlson Index and reported that only 34% of their patients had a greater than 2% chance 
of surviving 10 years, with only 6 patients having a greater than 50% chance of surviving 10 years. The majority of 
8 
 
these six patients also had some form of dementia. Fourteen (17%) of the patients in this cohort eventually needed 
to undergo surgical treatment due to disease progression, and this was performed under local anaesthetic. Several 
of the studies also changed management at progression to surgical intervention, suggesting that their cohort was in 
fact fit for surgery at entry. This is one of the main problems with the original RCTs, in which patients had to be fit for 
surgery at randomisation and these are not the type of patients in whom PET is likely to be beneficial. 
It must also be remembered when analysing the results of non-randomised studies that there is a great deal of 
heterogeneity in terms of the length of follow-up, type of PET or surgery, ER status, clinical assessment of response, 
patient fitness and co-morbid status and disease stage.  
Both Bouchardy et al [56] and Ali et al [57] demonstrated that patients treated with surgery had better overall and 
breast cancer-specific survival, in keeping with the analysis of the non-randomised studies. There are several issues 
pertaining to quality of the data from the population-based studies which is inherent to all registry-based data, 
including selection bias due to unrecorded factors (for example if there are differences in assignment of patients to 
treatment [67], missing data that results from the coding process, as well as being non-randomised. Bouchardy et al 
[56] found that one third of patients in their population had no histological or cytological confirmation of diagnosis, 
which leads to issues with determining oestrogen positivity, and in Ali et al’s study 18% had missing ER status [57]. 
Neither study examined the effect of co-morbidity on treatment assignment which clearly impacts on outcomes such 
as overall survival.  
A recent questionnaire study in the UK demonstrated that the use of PET remains widespread in the UK, with 93% of 
228 UK surgeons admitting to using it in early operable breast cancer, mostly for patients deemed unfit for surgery; 
however they also showed that 70% of respondents underestimated the average life-expectancy of an 80-year old 
women [10].  
 
Conclusion 
Primary endocrine therapy for breast cancer in elderly patients is popular in the UK, probably because it is a well-
tolerated [69], simple treatment that avoids hospitalisation. Whilst there are many non-randomised studies 
suggesting a significant benefit of surgery in older women with breast cancer the evidence is unreliable due selection 
bias in these studies. Therefore the Cochrane review of the RCTs of surgery with or without endocrine therapy 
versus PET remains the most reliable guide to the use of PET in these patients although is not representative of 
actual current UK practice where older frailer women, with ER +ve disease will be selected. The evidence 
demonstrates an advantage for surgery in terms of disease control and a likely survival benefit in patients with 
minimal or moderate comorbidity and a predicted life expectancy of five or more years. However, all of the RCTs 
selected patients who were fit for surgery under general anaesthesia, a factor that makes these studies non 
representative of normal UK practice where PET tends to be used in women who are unfit for or of borderline fitness 
for surgery. Inevitably therefor these trials have found in favour of surgery due to the relatively longer life 
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expectancy of such women. In contrast for patients with a much reduced life expectancy (e.g. less than two years) 
due to substantial comorbidity, the benefit of surgery over PET may be much less relevant.  Indeed subgroup analysis 
of data from 2 of the RCTs showed a survival advantage to surgery in women aged 70-75 but none in women over 75 
[70]. Cohort study data shows that there is little difference in rates of BCSS between groups of women having PET or 
surgery using current selection criteria which is reassuring but guidelines to aid selection are urgently needed. If PET 
is to be used, this review has found that AIs provide superior rates of disease control compared to Tamoxifen and 
should be used unless contra-indicated.    
References: 
1. Wanebo H, Cole B, Chung M, Vezeridis M, Schepps B, Fulton J, Bland K. Is surgical management compromised in 
elderly patients with breast cancer? Annals of Surgery. 1997; 225(5): 579-586. 
 
2. Sader C, Ingram D, Hastrich D. Management of breast cancer in the elderly by complete local excision and 
tamoxifen alone. Australian and New Zealand Journal of Surgery. 1999; 69(11): 790-793. 
 
3. Louwman W, Voogd A, van Dijck J, Nieuwenhuijzen G, Ribot J, JF P. On the rising trends of incidence and prognosis 
for breast cancer patients diagnosed 1975-2004: a long-term population-based study in southeastern 
Netherlands. Cancer Causes Control. 2008; 19(1): 97-106. 
 
4. Quinn M, Babb P, Brock A, Kirby L, Jones J. Cancer Trends in England and Wales, 1950 –1999. Studies on Medical 
and Population Subjects, No. 66. London, The Stationary Office: 42– 43. 2001. 
 
5. Diab S, Elledge R, Clark G. Tumor characteristics and clinical outcome of elderly women with breast cancer. Journal 
of the National Cancer Institute. 2000; 92(7): 550-556. 
 
6. Preece P, Wood R, Mackie C, Cuschieri A. Tamoxifen as initial sole treatment of localized breast-cancer in elderly 
women – a pilot study. British Medical Journal. 1982; 284(6319): 869-870. 
 
7. Wyld L, Reed MW. The need for targeted research into breast cancer in the elderly. British Journal of Surgery. 
2003; 90(4): 388-399. 
 
8. Chakrabarti J, Kenny F, Syed B, Robertson J, Blamey R, Cheung K. A randomised trial of mastectomy only versus 
tamoxifen for treating elderly patients with operable primary breast cancer-Final results at 20-year follow-up. Critical 
Reviews in Oncology Hematology. 2011; 78(3): 260-264. 
 
9. National Mastectomy and Breast Reconstruction Audit 2011. Leeds, National Health Service Information Centre. 
2011. 
 
10. Wylie S, Ravichandran D. A United Kingdom National Survey of Breast Surgeons on Primary Endocrine Therapy of 
Early Operable Breast Cancer. European Journal of Surgical Oncology. 2012; 38(5): 423. 
 
11. Monypenny I. UK Symptomatic breast audit 1.4.2001-31.3.2002. British Association of Surgical Oncology. 2003. 
 
12. Wyld L, Garg DK, Kumar ID, Brown H, Reed MW. Stage and treatment variation with age in postmenopausal 




13. Balakrishnan A, Ravichandran D. Early operable breast cancer in elderly women treated with an aromatase 
inhibitor letrozole as sole therapy. British Journal of Cancer. 2011; 105(12): 1825-1829. 
 
14. Dordea M, Jones R, Nicolas A, Sudeshna S, Solomon J, Truran P, Fetherson A, Iwuchukwu O. Surgery for breast 
cancer in the elderly - How relevant? The Breast. 2011; 20(3): 212-214. 
 
15. Osborn G, Jones M, Champ C, Gower-Thomas K, Vaughan-Williams E. Is primary endocrine therapy effective in 
treating the elderly, unfit patient with breast cancer? Annals of the Royal College of Surgeons of England. 2011; 
93(4): 286-289. 
 
16. Syed BM, Al-Khyatt W, Johnston SJ, Wong DW, Winterbottom L, Kennedy H, Green AR, Morgan DA, Ellis IO, 
Cheung KL. Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older 
women: a large series from a single centre. Br J Cancer. 2011; 104(9): 1393-1400. 
 
17. Traa MJ, Meijs CMEM, de Jongh MAC, van der Borst ECHM, Roukema JA. Elderly women with breast cancer often 
die due to other causes regardless of primary endocrine therapy or primary surgical therapy. The Breast. 2011; 20: 
365-369. 
 
18. Wink CJ, Woensdregt K, Nieuwenhuijzen GA, van der Sangen MJ, Hutschemaekers S, Roukema JA, Tjan-Heijnen 
VC, Voogd AC. Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. 
Annals of Surgical Oncology. 2012; 19(4): 1185-1191. 
 
19. Ayantunde AA, Gomez M, Ruhomauly N, Hoque H.  Primary Endocrine Therapy for Hormone Receptor Positive 
Breast Cancer: a Viable Treatment Alternative International Journal of Tumor Therapy 2012, 1(1): 1-5. 
 
20. Hille U, Soergel P, Länger F, Schippert C, Makowski L, Hillemanns P. Aromatase inhibitors as solely treatment in 
postmenopausal breast cancer patients. Breast Journal. 2012; 18(2): 145-150. 
 
21. Hussain T, Agarwal V, Garimella V, Rhadhakrishna S, Fox J, Kneeshaw P, Long E, Mahapatra T, McManus P, Lind 
M, Drew P, Cawkwell L. Clinical response to primary Letrozole therapy in women over 70 years with early breast 
cancer: A retrospective study with a 5 year follow up. European Journal of Surgical Oncology. 2012; 38(5): 433. 
 
22. Llombart-Cussac A, Guerrero A, Galan A, Caranana V, Buch E, Rodriguez-Lescure A, Ruiz A, Diana C, Porta V. 
Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with 
ER/PgR[ plus ] operable breast cancer. Clinical & Translational Oncology. 2012; 14(2): 125-131. 
 
23. Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast 
cancer in elderly women (70 years plus). Cochrane Database Systematic Reviews 2006; (1): CD004272. 
 
24. Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with 
operable breast cancer: cochrane review. British Journal of Cancer. 2007; 96(7): 1025-1029. 
25. Morgan JL, Reed MW, Wyld L.  Surgery versus primary endocrine therapy for operable primary breast cancer in 
elderly women (70 years plus). Cochrane Database Systematic Reviews. In press 2013. 
26. Robertson JFR, Todd JH, Ellis IO, Elston CW, Blamey RW. Comparison of mastectomy with tamoxifen for treating 
elderly patients with operable breast cancer. British Medical Journal. 1988;297:511-514. 
11 
 
27. Robertson JFR, Ellis IO, Elston CW, Blarney RW. Mastectomy or Operable Breast Tamoxifen as Initial Therapy for 
Cancer in Elderly Patients: 5Year Follow-up.  European Journal of Cancer 1992; 28A(4/5): 908-910. 
 
28. Johnston SJ, Kenney FS, Syed BM, Robertson JFR, Pinder SE, Winterbottom L, Ellis IO, Blamey RW, Cheung KL. A 
randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive 
breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up Annals of Oncology: 
Official Journal of the European Society for Medical Oncology. 2012; 23(9), 2296-2300. 
 
29. Chakrabarti J, Kenny FS, Syed BM, Robertson JFR, Blamey RW, Cheung KL. A randomised trial of mastectomy only 
versus tamoxifen for treating elderly patients with operable primary breast cancer—Final results at 20-year follow-
up. Critical Reviews in Oncology/Hematology. 2011; 78: 260–264. 
 
30. Willsher P, Robertson J, Jackson L, et al. Investigation of primary tamoxifen therapy for elderly patients with 
operable breast cancer. Breast 1997;6:150–54 
 
31. Capasso I, Nuzzo F, Labonia V, Landi G, Rossi E, de Matteis A. Surgery + tamoxifen versus tamoxifen as treatment 
of stage I and II breast cancer in over to 70 years old women: Ten years follow-up. Annals of Oncology. 2000; 
11(Suppl 4): 20. 
 
32. Mustacchi G, Ceccherini R, Milani S, Pluchinotta A, De Matteis A, Maiorino L, Farris A, 
Scanni A, Sasso F. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term 
results of the phase III randomized controlled multicenter GRETA trial. Annals of Oncology. 2003; 14: 414–420. 
 
33. Gazet JC, Ford HT, Coombes RC, Bland JM, Sutcliffe R, Quilliam J, Lowndes S. Prosepective randomized trial of 
tamoxifen vs surgery in elderly patients with breast cancer. European Journal of Surgical Oncology. 1994; 20: 207-
214. 
 
34. Gazet JC, Sutcliffe R. A randomised trial comparing tamoxifen vs. surgery in patients over the age of 70 with 
operable breast cancer - Final results after 28 years of follow-up. European Journal of Surgical Oncology. 2011; 37: 
754-757 
 
35. Fentiman JS, Christiaens MR, Paridaens R, Van Geel A, Rutgers E, Berner J, de Keizer G, Wildiers J, Nagadowska 
M, Legrand C, Therasse P. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 
10851 comparing tamoxifen alone with modified radical mastectomy. European Journal of Cancer. 2003; 39: 309–
316 
 
36. Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M. Late follow-up of a randomized trial of surgery 
plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. British Journal of 
Surgery 2004; 91: 699–704. 
 
37. Helleberg A, Lundgren B, Norin T, Sander S. Treatment of early localized breast cancer in elderly patients by 
Tamoxifen. British Journal of Radiology. 1982; 55: 511-515 
 
38. Nicholson S, Halcrow P, Sainsbury JRC, Angus B, Chambers P, Farndon JR, Harris AL. Epidermal growth factor 
receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with 




39. Mansi J, Smith I, Walsh G, A’hern RP, Harmer CL, Sinnett HD, Trott PA, Fisher C, McKinna JA. Primary medical 
therapy for operable breast cancer. European Journal of Cancer & Clinical Oncology 1989; 25(11): 1623-27 
 
40. Pain JA, Wickremesinghe SS, Bradbeer JW. Combined tamoxifen and anabolic steroid as primary treatment for 
breast cancer in the elderly. European Journal of Surgical Oncology. 1990; 16: 225-228. 
 
41. McDonald PJ, Carpenter R, Royle GT, Taylor I. Poor response of breast cancer to tamoxifen. Postgraduate Medical  
Journal. 1990; 66: 1029 - 1031 
 
42. Akhtar SS, Allan SG, Roger A, Chetty UDI, Smyth JF, Leonard RCF. A 10-year experience of tamoxifen as primary 
treatment of breast cancer in 100 elderly and frail patients. European Journal of Surgical Oncology. 1991; 30-35. 
 
43. Ciatto S, Bartoli D, Iossa A, Grazzini G, Cirillo A. Response of primary breast cancer to tamoxifen alone in elderly 
women. Tumori. 1991; 77: 328-330. 
 
44. Davies N, Moir G, Carpenter R, Cuthbert A, Herbert A, Royle GT, Taylor I. ERICA predicts response to tamoxifen in 
elderly women with breast cancer. Annals of the Royal College of Surgeons of England. 1991; 73: 361-363. 
 
45. Horobin JM, Preece PE, Dewar JA, Wood RAB, Cuschieri A. Long-term follow-up of elderly 
patients with locoregional breast cancer treated with tamoxifen only. British Journal of Surgery. 1991; 78: 213-217. 
 
46. Foudraine NA, Verhoef LCG, Burghouts JTM. Tamoxifen as Sole Therapy for Primary Breast Cancer in the Elderly 
Patient. European Journal of Cancer. 1992; 28A(415): 900-903. 
 
47. Low S, Dixon A, Bell J, Ellis IO, Elston CW, Robertson JFR, Blarney RW. Tumour oestrogen receptor content allows 
selection of elderly patients with breast cancer for conservative tamoxifen treatment. British Journal of Surgery. 
1992;79:1314–16. 
 
48. Bergman L, van Dongen JA, van Ooijen B, van Leeuwen EE. Should tamoxifen be a primary treatment choice for 
elderly breast cancer patients with locoregional disease? Breast Cancer Research and Treatment. 1995; 34: 77-83. 
 
49. Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK, Dowsett M. Prediction of Clinical 
Outcome from Primary Tamoxifen by Expression of Biologic Markers in Breast Cancer Patients. Clinical Cancer 
Research. 2000;6: 616-621. 
 
50. Kenny FS, Pinder SE, Ellis IO, Gee JMW, Nicholson RI, Bryce RP, Robertson JFR. Gamma linolenic acid with 
tamoxifen as primary treatment in breast cancer. International Journal of Cancer. 2000; 85: 643-648. 
 
51. Hooper SB, Hill, ADK, Kennedy S, Dijkstra B, Kelly LM, McDermott EWM, O’Higgins N. Tamoxifen as the primary 
treatment in elderly patients with breast cancer. Irish Journal of Medical Science. 2002; 171(1): 28-30. 
 
52. Gaskell D, Hawkins R, de Carteret S, Chetty U, Sangster K, Forrest APM. Indications for primary tamoxifen therapy 
in elderly women with breast cancer. British Journal of Surgery 1992;79:1317–20 
 
53. Rao VSR, Jameel JKA, Mahapatra TK, McManus PL, Fox JN, Drew PJ. Surgery Is Associated with Lower Morbidity 




54. Okunade G, Green AR, Ying M, Agrawal A, Paish EC, Aleskandrany M, Winterbottom L, Hassell K, Morgan DAL, 
Ellis IO, Cheung KL. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and 
response to primary endocrine therapy. Critical Reviews in Oncology/Hematology. 2009; 72: 76–82. 
 
55. Stotter A, Walker R. Tumour markers predictive of successful treatment of breast cancer with primary endocrine 
therapy in patients over 70 years old: A prospective study. Critical Reviews in Oncology/Hematology. 2010; 75: 249–
256. 
 
56. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schôfer P, et al. Undertreatment strongly 
decreases prognosis of breast cancer in elderly women. Journal of Clinical Oncology. 2003;21(19):3580-87. 
 
57. Ali AMG, Greenberg D, Wishart GC, Pharoah P. Patient and tumour characteristics, management, and age-
specific survival in women with breast cancer in the East of England. British Journal of Cancer. 2011; 104: 564 – 570. 
 
58. Gaskell D, Hawkins R, Sangsterl K, Chetty U, Forrest APM. Relation between immunocytochemical estimation of 
oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet. 1989;i:1044–
1046 
 
59. Coombes RC, Powles T, Berger U, Wilson P, McClelland RA, Gazet JC, Trott PA, Ford HT. Prediction of endocrine 
response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet. 
1987;ii:701–03 
 
60. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. 
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant 
treatment for breast cancer. Lancet. 2005; 365(9453): 60-62. 
 
61. Coombes R, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two 
to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of 
Medicine. 2004; 350(11): 1081-1092. 
 
62. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared 
with tamoxifen as initial adjuvant therapy for portmenopausal women with endocrine-responsive early breast 
cancer: update of study BIG 1–98. Journal of Clinincal Oncology. 2007;25: 486–92. 
 
63. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, et al. Letrozole is more effective neoadjuvant 
endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast 
cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology. 2001;19:3808–16. 
 
64. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus 
tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update 
of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology. 2003;21:2101–9. 
 
65. Dickman P, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Statistics in Medicine. 
2004;23(1):51-64. 
 
66. Satariano W, Ragland D. The effect of co-morbidity on 3-year survival of women with primary breast cancer. 




67. Grosclaude P, Colonna M, Hedelin G, Tretarre B, Arveux P, Lesec’h JM, et al. Survival of women with breast 
cancer in France: variation with age, stage and treatment. Breast Cancer Res Treat. 2001; 70: 137–143. 
 
68. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al. Management of elderly patients with breast 
cancer: update recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of 
Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012; 13(4): 148-160. 
 
69. Husain LS, Collins K, Reed MW, Wyld L. Choices in cancer treatment: a qualitative study of the older women's 
(>70 years) perspective. Psychooncology. 2008; 17(4): 410-416. 
 
70. Mustacchi G, Latteier J, Milani S, Bates T, Houghton J. Tamoxifen versus surgery plus tamoxifen as primary 
treatment for elderly patients with breast cancer: combined data from the “GRETA” and “CRC” trials. Proceedings of 
ASCO. 1998; 17(9a): [abstract 383]. 
 
 
Conflict of Interest Statement:  The authors declare that they have no conflict of interest. 
 
Role of funding source: No funding was received. 
 
Tables: 
Table 1: Characteristics of RCTs comparing PET with surgery 
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UK [33,34]  
100 TAM Mastectomy 

























NS NS 68% Up to 14 
years 
CRC, UK [36]  230 TAM Mastectomy 











I-III NS NS 53% Up to 16 
years 
aNS – Not stated; CR – Complete Response; PR – Partial Response; SD – Static Disease; TAM - Tamoxifen 


















Sweden [37]  
27 TAM¥ None 80 
(median) 






7% 19% 6-40 
Dundee I, UK 
[6]  
67 TAM¥ None 78.3 
(mean) 







27% 31% 36 
Newcastle, 
UK [38]  












23% 38% 14 
Royal 
Marsden I, 
UK [39]  
42 TAM¥ None 62  
(mean) 
NS I-III 95% 
CR 2%; 
PR 









51 TAM¥ None 78 
(median) 







20% NS 36 
Southampton 
I, UK [41]  
58 TAM¥ None 78.3 
(mean) 







31% 66% 19 
Edinburgh I, 
UK [42]  







10% NS 59 
Florence, 
Italy [43]  
62 TAM¥ None 78 
(median) 







3% 31% 48 
Southampton 
II, UK [44]  
56 TAM¥ None 79 
(median) 






29% 34% 60 
Dundee II, UK 
[45]  












40 TAM¥ None 82.4 
(mean) 
Unselected I-III 82% 
SD 
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I, UK [47]  
50 NS None 78 
(mean) 












84 TAM¥ None 83.6 
(median)  
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Marsden II, 
UK [49]  
54 TAM¥ None 83 
(median) 
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(14-55) 
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II, UK [50]  






17% NS NS 
Ireland [51]  68 TAM¥ None ≥70 Unselected I-IV 57% 
SD 
28% 




113 TAM¥ Surgery* 83.5 
(mean) 








Unselected I-III 58% 
SD 
11% 
13% 35% 31  
(1-102) 
bNS – Not stated; CR – Complete Response; PR – Partial Response; SD – Static Disease; TAM – Tamoxifen; AI – 
Aromatase Inhibitor 
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Leicester, 
UK [55]  
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Sunderlan
d, UK [14]  
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Wales [15]  82 TAM /AI None 81 
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ER+ NS NS NS 15% 24  
(6-72) 
Nottingha
m IV, UK 
[16]  













UK [19]  
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(medi
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0% 20% 51 
(19-78) 
Hull II, UK 
[21]  
45 LET¥ None 87 
(mea
n) 
ER+ NS 60% NS NS 60 
Valencia, 
Spain [22]  
56 LET¥ None 79  
(medi
an) 




0% NS 12 
cNS – Not stated; CR – Complete Response; PR – Partial Response; SD – Static Disease; TAM – Tamoxifen; AI – 
Aromatase Inhibitor; LET – Letrozole; ANZ – Anastrozole; *denotes included in the comparison of PET vs Surgery; ¥ 
denotes included in the comparison of Tamoxifen vs AI. 
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